Bays · Journal of clinical lipidology 2024 · expert review · n=?

Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024.

Cited 154 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Joint expert narrative review and clinical perspective statement without systematic review methodology

PubMed 38664184 · doi:10.1016/j.jacl.2024.04.001 · record verified 2026-08-30

What was done

A joint expert narrative review was conducted by the Obesity Medicine Association (OMA) and National Lipid Association (NLA) based on scientific literature, clinical perspectives of the authors, and organizational peer review to summarize pathophysiologic and clinical considerations regarding obesity, dyslipidemia, and cardiovascular disease risk.

What was found

The abstract reports that adipose tissue can store over 50% of total body free cholesterol and that triglycerides comprise up to 99% of adipose lipid species. Body fat percentages range from less than 5% to over 60%. Excess adiposity is linked to a modest rise in LDL-C and a typical dyslipidemia pattern consisting of elevated triglycerides, reduced HDL-C, increased non-HDL-C, elevated apolipoprotein B, increased LDL particle concentration, and increased small, dense LDL particles. Specific quantitative effect sizes or intervention statistics are not reported in the abstract.

Why it matters

This joint consensus highlights that because weight reduction yields only modest improvements in LDL-C, clinical management of patients with obesity must simultaneously target excess adiposity and atherogenic lipoproteins to effectively reduce cardiovascular disease risk.

Limits

The paper is an expert narrative review rather than a systematic review or meta-analysis, and the abstract provides no search strategy, study selection criteria, or quantitative trial outcomes.

Cited by